Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers

Stéphane Marot,Isabelle Malet,Valentin Leducq,Basma Abdi,Elisa Teyssou,Cathia Soulie,Marc Wirden,Christophe Rodriguez,Slim Fourati,Jean-Michel Pawlotsky,David Boutolleau,Sonia Burrel,Vincent Calvez,Anne-Geneviève Marcelin,Aude Jary

CLINICAL INFECTIOUS DISEASES（2022）

Cited 10|Views25

No score

Abstract

There are concerns about neutralizing antibodies' (NAbs') potency against severe acute respiratory syndrome coronavirus 2 variants. Despite decreased NAb titers elicited by BNT162b2 vaccine against VOC202012/01 and 501Y.V2 strains, 28/29 healthcare workers (HCWs) had an NAb titer >= 1:10. In contrast, 6 months after coronavirus disease 2019 mild forms, only 9/15 (60%) of HCWs displayed detectable NAbs against 501Y.V2 strain.

Translated text

Key words

COVID-19, vaccine, neutralizing antibodies, SARS-CoV-2 variants

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined